Skip to Main Content

Over glasses of Chablis at Fleming by Le Bilboquet in Manhattan, two longtime friends and biotech lifers hashed out the deal that will bring their wending and colorful careers back together after three decades.

Jeremy Levin, the professorial executive who has become one of the industry’s loudest voices on matters of social justice, is getting back into business with Sam Waksal, a hit-making drug developer with a gift for eloquence and a biography that doubles as biotech’s great unproduced screenplay.

advertisement

“We’ve got a collaboration that was made in heaven,” Waksal said, grinning, in an interview.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect

To submit a correction request, please visit our Contact Us page.